From the clinical perspective, RNA interference targeting of Vanguard conferred PARP inhibitor (PARPi) sensitivity to human breast cancer cells bearing wild‐type (WT) Breast Cancer gene 1 (BRCA1) expression, suggesting targeting Vanguard has practical utility in synthetic lethal approaches used to target these cancers. Here, BRCA1 is linked to breast cancer.